SBFM · Sunshine Biopharma Inc.

$1.67 -0.04 (-2.34%) At close · Jul 24

Market Cap

$8.31M

5.01M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2023

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Mr. Camille Sebaaly	CFO	$315,000	$380,000	—	—	—	—	$695,000
Dr. Steve N. Slilaty	CEO	$378,000	$182,000	—	—	—	—	$560,000
Dr. Abderrazzak Merzouki	COO	$252,000	$8,000	—	—	—	—	$260,000

Fiscal 2022

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Mr. Camille Sebaaly	CFO	$300,000	$630,000	—	—	—	—	$930,000
Camille Sebaaly	CFO	$300,000	$630,000	—	—	—	—	$930,000
Dr. Abderrazzak Merzouki	COO	$240,000	$245,000	—	—	—	—	$485,000
Dr. Steve N. Slilaty	CEO	$360,000	$10,000	—	—	—	—	$370,000

Fiscal 2021

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Dr. Steve N. Slilaty	CEO	$156,380	—	$306,000	—	—	—	$462,380
Dr. Abderrazzak Merzouki	COO	$109,927	—	$306,000	—	—	—	$415,927
Camille Sebaaly	CFO	$40,000	—	$306,000	—	—	—	$346,000

Key facts CIK 1402328 CUSIP 867781809 13F (30d) 3 filings 3 filers Visit website Investor relations